A simulation-based bias analysis to assess the impact of unmeasured confounding when designing nonrandomized database studies
American Journal of Epidemiology · 2024
DOI: 10.1093/aje/kwae102 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Epidemiology, 2024. Verfasst von Rishi J Desai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 0212…. Hauptthemen laut MEDLINE: Bias, Confounding Factors, Epidemiologic, Computer Simulation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Unmeasured confounding is often raised as a source of potential bias during the design of nonrandomized studies, but quantifying such concerns is challenging. We developed a simulation-based approach to assess the potential impact of unmeasured confounding during the study design stage. The approach involved generation of hypothetical individual-level cohorts using realistic parameters, including a binary treatment (prevalence 25%), a time-to-event outcome (incidence 5%), 13 measured covariates, a binary unmeasured confounder (u1; 10%), and a binary measured “proxy” variable (p1) correlated with u1. Strengths of unmeasured confounding and correlations between u1 and p1 were varied in simulation scenarios. Treatment effects were estimated with (1) no adjustment, (2) adjustment for measured confounders (level 1), and (3) adjustment for measured confounders and their proxy (level 2). We computed absolute standardized mean differences in u1 and p1 and relative bias with each level of adjustment. Across all scenarios, level 2 adjustment led to improvement in the balance of u1, but this improvement was highly dependent on the correlation between u1 and p1. Level 2 adjustments also had lower relative bias than level 1 adjustments (in strong u1 scenarios: relative bias of 9.2%, 12.2%, and 13.5% at correlations of 0.7, 0.5, and 0.3, respectively, vs 16.4%, 15.8%, and 15.0% for level 1). An approach using simulated individual-level data is useful to explicitly convey the potential for bias due to unmeasured confounding while designing nonrandomized studies, and can be helpful in informing design choices. This article is part of a Special Collection on Pharmacoepidemiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02120, United States.
- Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, United States.
- Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, United States.
ORCID-Profile: Rishi J Desai
Zitieren
APA
Desai, R. J., Bradley, M. C., Lee, H., Eworuke, E., Weberpals, J., Wyss, R., Schneeweiss, S., & Ball, R. (2024). A simulation-based bias analysis to assess the impact of unmeasured confounding when designing nonrandomized database studies. American Journal of Epidemiology. https://doi.org/10.1093/aje/kwae102
Vancouver
Desai RJ, Bradley MC, Lee H, Eworuke E, Weberpals J, Wyss R, et al. A simulation-based bias analysis to assess the impact of unmeasured confounding when designing nonrandomized database studies. American Journal of Epidemiology. 2024. doi:10.1093/aje/kwae102
BibTeX
@article{Desai2024,
author = {Desai, Rishi J and Bradley, Marie C and Lee, Hana and Eworuke, Efe and Weberpals, Janick and Wyss, Richard and Schneeweiss, Sebastian and Ball, Robert},
title = {A simulation-based bias analysis to assess the impact of unmeasured confounding when designing nonrandomized database studies},
journal = {American Journal of Epidemiology},
year = {2024},
doi = {10.1093/aje/kwae102}
}
EUVIMED